KRAS inhibitors represent a promising therapeutic frontier in pancreatic ductal adenocarcinoma (PDAC) treatment. However, the clinical benefit of KRAS inhibitors in PDAC is limited by the frequent emergence of resistance. Here, we demonstrated that acquisition of resistance to KRAS inhibitors rendered PDAC cells hypers...
Si-Han Huo, Hai-Long Zhao, Tong Liu et al.· Cancer Research· 0 citations
This review systematically summarizes the complex regulatory mechanisms of ITM2A in growth, development, and disease, with a particular focus on skeletal development and tumorigenesis, aiming to provide a theoretical basis for its potential use as a biomarker for development and disease diagnosis/treatment, as well as...
Xiaoling Deng, Yi-Fang Wang, Lan Yang et al.· iScience· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.